Your browser doesn't support javascript.
loading
Myeloid/lymphoid neoplasm with ZMYM2::FGFR1 rearrangement: A complex trilineage phenotypic and clonal evolution with associated genomic alterations.
Chen, Dong; Liu, Guang; Lewis, Michael R; Li, Xia; Ulrickson, Matthew; Nath, Rajneesh; Chen, Weina.
Afiliação
  • Chen D; Pathology and Laboratory Medicine, University of Connecticut, Farmington, CT, United States.
  • Liu G; Department of Pathology, University of Arizona, College of Medicine, Phoenix, AZ, United States.
  • Lewis MR; Banner MD Anderson Cancer Center at Banner Gateway Medical Center, Gilbert, AZ, United States.
  • Li X; Department of Pathology, University of Arizona, College of Medicine, Phoenix, AZ, United States.
  • Ulrickson M; Banner MD Anderson Cancer Center at Banner Gateway Medical Center, Gilbert, AZ, United States.
  • Nath R; Banner MD Anderson Cancer Center at Banner Gateway Medical Center, Gilbert, AZ, United States.
  • Chen W; University of Texas Southwestern Medical Center, Dallas, TX, United States.
Leuk Res Rep ; 19: 100370, 2023.
Article em En | MEDLINE | ID: mdl-37275466
We report a case of myeloid/lymphoid neoplasm with ZMYM2::FGFR1 rearrangement (MLNZMYM2::FGFR1) exhibiting a complex disease evolution. This neoplasm initially presented as T-lymphoblastic lymphoma (T-LBL) in lymph node and myeloproliferative neoplasm (MPN) with eosinophilia in bone marrow, then transitioned to systemic mastocytosis (SM) likely accompanied by additional JAK3 and other mutations and finally transformed to acute myeloid leukemia (AML) accompanied by additional/secondary genetic abnormality (gain of chromosome 21, der(13)t(8;13), and RUNX1 mutation). To our knowledge, this is the first case of MLNZMYM2::FGFR1 with a complex trilineage/phenotypic [T-cell (T-LBL), mast cell (SM), and myeloid (MPN and AML)] lineage evolution.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Risk_factors_studies Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Risk_factors_studies Idioma: En Ano de publicação: 2023 Tipo de documento: Article